7 August 2025

Biosimilars PBAC

Biosimilars denosumab and tocilizumab head to PBAC

7 December 2023

Ankylosing Spondylitis Biosimilars PBS

AS biosimilars script approval goes online

19 October 2023

Biosimilars FDA

Toci biosimilars approved overseas

24 August 2023

Biologics Biosimilars Rheumatoid Arthritis

Biosimilar multi-switching is a go

2 February 2023

Biosimilars COVID-19 Paediatric PBAC PBS

Groundhog day for Evusheld’s PBS quest

8 December 2022

Ankylosing Spondylitis Biosimilars Scleroderma Spondyloarthritis

Good news: you’re trusted

4 August 2022 SPONSORED

Biosimilars

Biosimilars driving $1 billion dollars of PBS savings

14 July 2022 SPONSORED

Biosimilars

The promise of biosimilars realised

21 October 2021

Ankylosing Spondylitis Biologics Biosimilars Conditions O&G

How to help patients understand their biosimilar options

8 July 2021 SPONSORED

Biosimilars FDA Spondyloarthritis

How might subcutaneous infliximab impact the lives of your patients with RA?

15 April 2021 SPONSORED

Biosimilars

Will the promise of biosimilars ever be realised in Australia?

3 March 2021 SPONSORED

Biosimilars Plaque psoriasis Spondyloarthritis

ADDING BIOSIMILARS TO YOUR ARMAMENTARIUM

3 February 2021 SPONSORED

Biosimilars Spondyloarthritis

FURTHER YOUR EDUCATION WITH SANDOZ IN 2021

12 November 2020

Biosimilars

New biosimilars and their implications explained

30 August 2018

Biosimilars Conditions

Early traction on biosimilars push